The treatment of hypertensive asthmatic subjects with highly selective β blocker - nebivolol - 25/08/11
Abstract |
Rationale |
The benefit from using selective β blockers due to arterial hypertension and ischaemic heart disease is well known. Asthmatic subjects are the special “group of risk” with relative contraindications for this therapy. The novel highly selective β blocker nebivolol which additionally posses vasodilatatory effect through nitric oxide release is potentially safe in asthma.
Methods |
The aim of the study was to evaluate the influence of one dose 5 mg of nebivolol orally administrated compared with placebo to spirometric parameters and blood pressure. The study was performed double-blind cross–over method in 7 patient with mild/moderate persistent asthma. The patients were treated with nebivolol or placebo with 7 days of “wash–out”. The spirometry was done at 0, 2 h, 6h and 24 h after administration. Blood pressure was measured continuously through 24 hours.
Results |
None of the patient reacted with dyspnoe or with significant fall of FEV1. In all cases a moderate but significant decrease of blood pressure was observed.
Conclusions |
Nebivolol seems to be a safe and effective in treatment asthmatic hypertensive patients.
Le texte complet de cet article est disponible en PDF. | Funding: Medical University of Lodz |
Vol 113 - N° 2S
P. S277 - février 2004 Retour au numéro
Article précédent
- Preventing false spirometry values and invalid symptom scores in respiratory clinical trials
- S.A. Raymond, T. Blackadar, W. Oueida, N.E. Ohlenbusch
- No evidence of increased sputum eosinophilia in treated asthma patients with gastroesophageal reflux
- V. Mehta, A. Madaan, C.K. Kim, J.B. Hagan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?